Sruthi Adimadhyam is a Research Scientist in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. A pharmacoepidemiologist by training, her interests include evaluation and confirmation of post-marketing safety signals, comparative effectiveness research, and methods to mitigate bias in observational studies of newly approved medications. She currently works on the FDA-sponsored Sentinel Initiative monitoring post-marketing safety of regulated medical products. Dr. Adimadhyam received her doctorate in pharmacy from the University of Illinois at Chicago. Her doctoral dissertation focused on determining the comparative safety of a new class of oral anti-hyperglycemic agents using administrative claims data.